Positive Initial Findings from Xilio Therapeutics on XTX101
In a recent announcement, Xilio Therapeutics, Inc. (Nasdaq: XLO), a pioneering clinical-stage biotechnology company, revealed initial results from its ongoing Phase 1C clinical trial involving vilastobart (XTX101). This innovative approach combines vilastobart, a tumor-activated anti-CTLA-4 monoclonal antibody, with atezolizumab, a PD-(L)1 inhibitor, to combat advanced solid tumors.
Early Encouraging Signs of Efficacy
The initial clinical trial data indicated promising anti-tumor activity. Notably, there were unconfirmed partial responses observed in patients with challenging “cold” tumors — those which typically resist immunotherapy treatments. A remarkable outcome was the complete resolution of a metastatic liver lesion in a patient suffering from microsatellite stable colorectal cancer (MSS CRC).
Safety Profile Indicates Tolerance
Importantly, the combination of vilastobart and atezolizumab has shown to be generally well-tolerated among participants. The initial safety data suggest that vilastobart may serve as a differentiated next-generation anti-CTLA-4 therapy, especially when used in conjunction with PD-(L)1 inhibitors, providing hope for patients with limited treatment options.
Participants and Treatment Regimen
As of the latest data cutoff, the trial included 17 patients treated with varying doses of vilastobart and atezolizumab. Specifically, vilastobart was administered at doses between 75 mg and 150 mg every six weeks, while atezolizumab was given at 1200 mg every three weeks. Among those treated, the patient demographics revealed a median age of 69 years, showcasing a cohort largely consisting of individuals who have undergone multiple prior lines of therapy.
Continued Enrollment in Phase 1C
Despite the challenges faced, some patients continue their treatment protocol, while others have discontinued due to various reasons. The trial remains active, contributing crucial knowledge to the treatment landscape for advanced solid tumors.
Initial Anti-Tumor Activity Highlights
Of notable interest are the results related to anti-tumor activity within the trial. Two patients, one with MSS CRC and another with ampullary carcinoma, exhibited unconfirmed partial responses. These findings highlight not only the critical nature of ongoing treatment adaptations but also the potential benefits of combining therapies in immuno-oncology.
Clinical Development Moving Forward
Building off this initial data, Xilio plans to continue the exploration of vilastobart's efficacy and safety in larger patient populations. Their development strategy includes a focus on both MSS CRC and a variety of other advanced solid tumors that have historically shown resistance to current treatment modalities.
Looking Ahead: Future Data and Trials
The excitement surrounding the combination of vilastobart and atezolizumab is bolstered by the upcoming presentation of initial Phase 2 data, where expectations are high for broader efficacy in the treatment of MSS CRC. Anticipated results for additional patients will further detail the impact of this novel therapy.
Investor Conference Call Information
Xilio Therapeutics will host an investor conference call and webcast to discuss these updates in detail. The call will feature insights from management alongside experts in the field to bolster understanding of the trial's implications.
Frequently Asked Questions
What is the significance of the trial findings for vilastobart?
These findings suggest that vilastobart in combination with atezolizumab may provide effective options for patients who have historically faced limited treatment success, particularly in immuno-resistant tumors.
How many patients were included in the initial trial?
Seventeen patients participated in the Phase 1C trial to evaluate the safety and efficacy of vilastobart combined with atezolizumab.
What types of cancer are being targeted in the trial?
The trial primarily targets advanced solid tumors, including MSS colorectal cancer, which is notably challenging to treat.
When can we expect further data releases from Xilio Therapeutics?
Further data, particularly from the Phase 2 trials, are expected to be released later this year and into the next, with ongoing patient enrollment contributing to these studies.
Who is involved in the Xilio Therapeutics development team?
The team includes pharmaceutical experts and oncologists committed to advancing innovative immuno-oncology therapies aimed at improving patient outcomes.
